Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen...(ed patients in the developed world is ca...),Health

Date:7/30/2009

ed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. To learn more about PKU, please visit www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R)( )(galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R)( )(sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.B
'/>"/>

SOURCE BioMarin Pharmaceutical Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related medicine news :

1. 90 Brain Fitness Patents for Posit Science
2. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
3. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
4. Impliant Granted Two New U.S. Patents and Successfully Defends European Patent Opposition Case
5. CAP Joins Landmark Lawsuit Challenging Legality of Myriad Genetics Gene Patents
6. ACMG Joins Lawsuit Challenging Patents on Breast Cancer Genes; Genes Are Naturally Occurring Substances and Should Not Be Patented, Says American College of Medical Genetics
7. ACLU Challenges Patents on Breast Cancer Genes
8. MMR Information Systems, Inc. Announces 250,000 Membership Milestone and Granting of International Patents
9. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
10. United States Patent Office Rejects KCIs Patents
11. ALSIUS CORPORATION PREPARED TO INVALIDATE ZOLL TEMPERATURE MANAGEMENT PATENTS